Lilly launches TuneLab platform to give biotechnology companies access to AI-enabled drug discovery models built through over $1 billion in research investment

Program provides access to Lilly-trained artificial intelligence to help accelerate breakthrough medicines

New offering expands Lilly Catalyze360's support for early-stage drug development

INDIANAPOLIS, Sept. 9, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the launch of Lilly TuneLab, an artificial intelligence and machine learning (AI/ML) platform that provides biotech companies access to drug discovery models trained on years of Lilly's research data. Lilly estimates that this first release of AI models includes proprietary data obtained at a cost of over $1 billion, representing one of the industry's most valuable datasets used to train an AI system available to biotechnology companies. 

"Lilly has spent decades building comprehensive datasets for drug discovery. Today, we're sharing the intelligence gained from that investment to help lift the tide of biotechnology research," said Daniel Skovronsky, M.D., Ph.D., chief scientific officer, and president, Lilly Research Laboratories and Lilly Immunology. "Lilly TuneLab was created to be an equalizer so that smaller companies can access some of the same AI capabilities used every day by Lilly scientists. By opening up access, we hope to accelerate the creation of new medicines for patients who need them." 

Lilly TuneLab is powered by Lilly's full drug disposition, safety, and preclinical datasets representing experimental data obtained with hundreds of thousands of unique molecules. In return for access, selected biotech partners contribute training data, which fuels continuous improvement for the benefit of others in the ecosystem and ultimately patients. The platform is hosted by a third-party and employs federated learning, a privacy-preserving approach that enables biotechs to tap into Lilly's AI models without directly exposing their proprietary data or Lilly's. Lilly TuneLab was developed through partnerships with leading global technology providers and AI/ML experts. Lilly intends to extend the platform's features and capabilities beyond this first release, including adding in vivo small molecule predictive models, available exclusively on Lilly TuneLab.

Lilly TuneLab is the newest addition to Lilly Catalyze360's set of offerings for Lilly's biotech partners, which includes strategic capital through Lilly Ventures, state-of-the-art laboratory facilities at Lilly Gateway Labs, and drug development expertise via Lilly ExploR&D.

"For many early-stage biotech companies, the promise of AI and machine learning in drug discovery remains just that — a promise. While the industry buzzes about the power of AI/ML to accelerate innovation, most small biotechs face a fundamental hurdle: they simply don't have access to the large-scale, high-quality data needed to impact decisions and train truly effective models," said Nisha Nanda, Ph.D., group vice president and head, Lilly Catalyze360. "With Lilly TuneLab we're not just sharing resources, we are also compressing decades of learning into instantly accessible intelligence. Through this platform, we can help our biotech partners unlock novel scientific insights, make smart development decisions earlier, and increase their likelihood of success." 

To learn more about Lilly TuneLab and explore partnership opportunities, visit tunelab.lilly.com.

About Lilly
Lilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit Lilly.com and Lilly.com/news, or follow us on Facebook, Instagram, and LinkedIn. P-LLY

Trademarks and Trade Names
All trademarks or trade names referred to in this press release are the property of the company, or, to the extent trademarks or trade names belonging to other companies are references in this press release, the property of their respective owners. Solely for convenience, the trademarks and trade names in this press release are referred to without the ^® and ™ symbols, but such references should not be construed as any indicator that the company or, to the extent applicable, their respective owners will not assert, to the fullest extent under applicable law, the company's or their rights thereto. We do not intend the use or display of other companies' trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies.

Lilly Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about Lilly Catalyze360 and Lilly TuneLab and reflects Lilly's current beliefs and expectations. However, there can be no assurance that Lilly Catalyze360 and/or Lilly TuneLab will achieve Lilly's objectives or that Lilly will execute its strategy as planned. For further discussion of risks and uncertainties relevant to Lilly's business that could cause actual results to differ from Lilly's expectations, see Lilly's Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this release.

SOURCE Eli Lilly and Company